Skip to main content

For Patients

Utility Navigation

Dosage Chart

Coupons

Breadcrumb

Home
Healthcare Practitioner Contact Form

Relieves symptoms 4x faster than Rx

Close

Main navigation

Efficacy
Pregnancy
Diabetes
Product & Dosage
Resources
Coupons for Your Patients

Healthcare Practitioner Contact Form

If you are a customer and would like to reach our customer service team, please click here or call us: 877-666-4782

First Name

Last Name

Phone

Your email address

Business Address

Suite #

City/Town

State / Province

Zip Code

Message

Out of your last 10 Vaginal Yeast Infection patients, how many times did you recommend Monistat?

MONISTAT® EXTERNAL VULVAR CREAM
Miconazole Nitrate Cream (2%)

EXTERNAL USE ONLY. RELIEVES external vulvar itching and irritation due to a Vaginal Yeast Infection.

Directions: To Open: Use cap to puncture seal. Squeeze a small amount of cream onto your fingertip. Apply to skin outside the vagina (vulva) that itches and is irritated. Use 2 times daily for up to 7 days, as needed.

Active ingredient: miconazole nitrate (2%)

Inactive Ingredients: bensoic acid, cetyl alcohol, isopropyl myristate, polysorbate 60, potassium hydroxide, propylene glycol, purified water, stearyl alcohol
Store at 68°-77°F (20°-25° C).

For external vulvar use only. Do not take by mouth or use in eyes. Keep out of reach of children.

Footer Navigation

Privacy Notice
Contact Us
Cookie Policy
Terms of Use

This website is intended for healthcare professionals in the US or its territories.

©2024 Insight Pharmaceuticals LLC, Tarrytown, NY, a Prestige Consumer Healthcare company.

*Based on number of members
†vs all first-line prescription drug products
‡Based on a clinical study with MONISTAT® Combination Pack Ovule® treatment vs the leading prescription product
§2015 CDC Guidelines recommend the use of 7-day topical azole therapies for treatment of vulvovaginal candidiasis (VVC) in pregnant women.
¶Per 2015 CDC Guidelines, options for first-line therapy of non-albicans VVC include longer duration therapy (7-14 days) with a non-fluconazole azole regimen.

REFERENCES: 1. van Heusden AM, Merkus HM, Corbeij HS, et al. Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. Acta Obstet Gynecol Scand. 1990;69(5):417-422. 2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. http://www.cdc.gov/std/tg2015/tg-2015-print.pdf. Published June 5, 2015. Accessed August 14, 2015. 3. Marchaim D, Lemanek L, Bheemreddy B, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407-1414. 4. Mintz, Martens MG. Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology. Adv Infect Dis. 2013;3(4):238-242. 5. Data on file. Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company. Tarrytown, NY; 2015. 6. Samra-Latif OM. Vulvovaginitis. http://emedicine.medscape.com/article/2188931-overview. Published March 27, 2014. Accessed March 12, 2015. 7. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA. 2016;315(1):58-67. 8. US Food and Drug Administration. FDA Drug Safety Communication: FDA to review study examining use of oral fluconazole (Diflucan) in pregnancy. https://www.fda.gov/Drugs/DrugSafety/ucm497482.htm. Published April 26, 2016. Accessed January 22, 2018. 9. Goswami D, Goswami R, Banerjee U, et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect. 2006;52(2):111-117. 10. Nyirjesy P and Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2015;125(3):33-46. 11. May M and Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69-83. 12. Diflucan [prescribing information]. New York, NY: Roerig. 2013. 13. Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840-848. 14. A 2017 survey of OB/GYNs (n=200) asked: Which of the following best describes your approach to prescribing fluconazole for yeast infection in pregnant patients? (Throughout pregnancy; Trimesters 2 and 3; Trimester 3; Do not prescribe during pregnancy). 15. A 2017 survey of OB/GYNs (n=200) asked: When treating a vaginal yeast infection in women with diabetes, which do you recommend most often? (Butoconazole; Fluconazole; Miconazole; Terconazole). 16. ISSVD. (2019). Vulvovaginal Candidiasis: Diagnosis and Treatment Tips (Version 1.3) [Mobile application software]. Retrieved from http://itunes.apple.com. 17. Postelnick M. Yeast infections in pregnancy: recommended treatments. http://www.medscape.com/viewarticle/866590. Published July 29, 2016. Accessed August 26, 2017. 18. Richter SS, et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-2162. 19. Hylton Gravatt LA, Flurie RW, Lajthia E, Dixon DL. Clinical guidance for managing statin and antimicrobial drug-drug interactions. Curr Atheroscler Rep. 2017;19:46. 20. A 2017 survey of OB/GYNs (n=200) and women’s health NPs and PAs (n=200) asked: Compared to your past prescribing practices (e.g., 3-5 years ago), how often do you currently prescribe more than one pill of fluconazole (150 mg) for uncomplicated vaginal yeast infection (i.e., mild-to-moderate and infrequent)? (More often, Less often, About the same, Do not prescribe). 21. A 2017 survey of OB/GYNs (n=200) and women’s health NPs and PAs (n=200) asked: In patients unresponsive to a single 150 mg dose of fluconazole, how often have you suspected microbial resistance? (Often, Occasionally, Rarely, Never). 22. Bérard A, Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019;191:E179-E187. 23. IRI Vaginal Antifungal Category Latest 52 Week Pd Ending 09-06-20.